Follow
Guillemette Emma Benoist
Guillemette Emma Benoist
Radboud university medical center
Verified email at radboudumc.nl
Title
Cited by
Cited by
Year
Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide
GE Benoist, RJ Hendriks, PFA Mulders, WR Gerritsen, DM Somford, ...
Clinical pharmacokinetics 55 (11), 1369-1380, 2016
792016
Drug–drug interaction potential in men treated with enzalutamide: Mind the gap
GE Benoist, IM van Oort, S Smeenk, A Javad, DM Somford, DM Burger, ...
British journal of clinical pharmacology 84 (1), 122-129, 2018
432018
Analytical challenges in quantifying abiraterone with LC–MS/MS in human plasma
GE Benoist, E van der Meulen, FJE Lubberman, WR Gerritsen, TJ Smilde, ...
Biomedical chromatography 31 (11), e3986, 2017
232017
Prognostic value of novel liquid biomarkers in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: a prospective observational study
GE Benoist, IM van Oort, E Boerrigter, GW Verhaegh, O van Hooij, ...
Clinical Chemistry 66 (6), 842-851, 2020
212020
Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical …
GE Benoist, E van der Meulen, IM van Oort, JH Beumer, DM Somford, ...
Therapeutic drug monitoring 40 (2), 222, 2018
82018
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
FJE Lubberman, GE Benoist, W Gerritsen, DM Burger, N Mehra, ...
Cancer chemotherapy and pharmacology 84 (6), 1179-1185, 2019
72019
The combination of enzalutamide and opioids: a painful pitfall
GE Benoist, IM van Oort, DM Burger, BCP Koch, N Mehra, NP van Erp
Eur Urol 75 (2), 351-352, 2019
72019
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line …
E Boerrigter, GE Benoist, IM van Oort, GW Verhaegh, O van Hooij, ...
Molecular Oncology 15 (9), 2453-2465, 2021
62021
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
GE Benoist, IM van Oort, DM Burger, N Mehra, NP van Erp
Cancer Chemotherapy and Pharmacology 85 (4), 753-760, 2020
42020
Hormone therapy in prostate cancer; a pharmacotherapeutic challenge
H Westdorp, GE Benoist, HJ Schers, PH Van Erp, WR Gerritsen, ...
Nederlands tijdschrift voor geneeskunde 159, A9250-A9250, 2015
42015
A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer
GE Benoist, MJ van der Doelen, R Ter Heine, NP van Erp, N Mehra
British Journal of Clinical Pharmacology 84 (5), 1064-1067, 2018
22018
The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
E Boerrigter, GE Benoist, JK Overbeek, R Donders, N Mehra, IM van Oort, ...
British Journal of Clinical Pharmacology 88 (3), 1170-1178, 2022
12022
Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance
G Cantet, A Berges, R O'Sullivan, S Cohen‐Rabbie, C Dota, V Dubois, ...
British Journal of Clinical Pharmacology 88 (3), 1010-1019, 2022
12022
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
E Boerrigter, GE Benoist, IM van Oort, GW Verhaegh, AFJ de Haan, ...
Cancers 13 (24), 6279, 2021
12021
Integrating pharmacokinetics and molecular biomarkers in advanced prostate cancer
GE Benoist
[Sl: sn], 2019
12019
CLINICAL TRIAL SIMULATIONS SHOW GOOD PERFORMANCE OF THE CONCENTRATION-QT MODEL IN CLINICAL ONCOLOGY SETTINGS.
G Cantet, A Berges, S Cohen-Rabbie, D RekiA, J Parkinson, C Dota, ...
CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S8-S8, 2021
2021
Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective …
E Boerrigter, GE Benoist, IM van Oort, GW Verhaegh, O van Hooij, ...
Cancer Research 80 (16_Supplement), 1413-1413, 2020
2020
Does a food intervention makes abiraterone treatment affordable?
NP Van Erp, GE Benoist, WR Gerritsen, N Mehra, D Burger, P Hamberg, ...
Journal of Clinical Oncology 37 (15_suppl), e16523-e16523, 2019
2019
Exploring the prognostic value of novel liquid biomarkers in patients with metastatic castration resistant prostate cancer treated with enzalutamide: a prospective …
GE Benoist, IM van Oort, GW Verhaegh, O van Hooij, L Groen, F Smit, ...
Integrating pharmacokinetics and molecular biomarkers in advanced prostate …, 2019
2019
CASE REPORT A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer
GE Benoist, MJ van der Doelen, R ter Heine, NP van Erp, N Mehra
Br J Clin Pharmacol, 1, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–20